biote (NASDAQ:BTMD – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported $0.01 earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $43.33 million during the quarter, compared to the consensus estimate of $44.01 million. biote had a net margin of 3.19% and a negative return on equity of 22.33%.
Here are the key takeaways from biote’s conference call:
- Procedure revenue remained under pressure: Q3 revenue fell 9.6% to $43.3 million, while procedure revenue declined 15.1% to $28.9 million, with the January recall contributing to slower-than-expected recovery. Management cited modest improvement in average daily procedure volume but said sustained growth still requires work.
- Profitability declined sharply year over year: Net income was $0.6 million versus $9.2 million a year earlier, and diluted EPS was $0.01 versus $0.22. Gross margin fell to 67.7% from 71.8%, partly due to reliance on lower-margin third-party pellets.
- Gross margin showed sequential recovery: It improved 231 basis points from Q2 as pellet sourcing shifted back toward Biote’s internally manufactured supply. Asteria Health was back to pre-recall levels and expected to supply more than half of shipped pellets.
- Supplements continued to grow: Revenue rose 7.3% to $12.0 million, primarily driven by the e-commerce channel.
- Full-year 2026 guidance was maintained at revenue above $175 million and Adjusted EBITDA above $25 million. Management pointed to encouraging procedure trends, while emphasizing that improved sales productivity, clinic retention, and practitioner engagement remain necessary to restore growth.
biote Stock Performance
BTMD traded up $0.11 during trading on Wednesday, reaching $1.23. 105,562 shares of the stock were exchanged, compared to its average volume of 106,590. The stock has a market cap of $44.19 million, a P/E ratio of 3.29 and a beta of 1.73. biote has a twelve month low of $1.00 and a twelve month high of $2.98. The stock’s 50 day moving average price is $1.27 and its two-hundred day moving average price is $1.81.
Analyst Upgrades and Downgrades
BTMD has been the subject of several recent analyst reports. TD Cowen dropped their price objective on shares of biote from $2.50 to $2.00 and set a “buy” rating for the company in a report on Friday, August 7th. Weiss Ratings lowered biote from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 13th. Finally, B. Riley Financial decreased their price target on biote from $2.00 to $1.50 and set a “neutral” rating on the stock in a research report on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, biote currently has a consensus rating of “Moderate Buy” and an average target price of $2.50.
Check Out Our Latest Report on biote
Insiders Place Their Bets
In other biote news, Chairman Marc Beer purchased 115,950 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average price of $1.53 per share, for a total transaction of $177,403.50. Following the purchase, the chairman owned 223,744 shares in the company, valued at approximately $342,328.32. The trade was a 107.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 32.40% of the stock is currently owned by company insiders.
biote Company Profile
Biote Inc (NASDAQ: BTMD) is a healthcare company focused on hormone optimization and personalized care. Through its provider-enabled platform, the company supports physicians and other healthcare professionals who offer bioidentical hormone replacement therapy and related wellness services.
The company’s offerings include the Biote Method, a hormone pellet therapy program designed for eligible men and women, as well as nutritional supplements, patient education, clinical training, and practice-management support.
See Also
- Five stocks we like better than biote
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.
